Overcoming vaccine hesitancy
Our best hope of charting a course to a post-pandemic world
Early diagnosis is key to prevention of potentially fatal complication in type 1 diabetes
New RI-MUHC study of international data suggests awareness and access to care are key factors in improving...
New study of hydroxychloroquine usage may help personalize lupus treatment
RI-MUHC researchers identify factors associated with poor outcomes for lupus patients
Reaching new heights by working together: Innovative industry partnership
RI-MUHC-led team will use artificial intelligence to improve survival rates of cancer-diagnosed patients
Two studies confirm efficiency of saliva tests for COVID-19
Testing is the cornerstone of the fight against COVID-19, and a test that can be self-administered would greatly increase the options for case...
Saliva samples for COVID-19 testing: as good as nasopharyngeal swabs, but cheaper
New meta-analysis of 37 studies and over 7,000 paired saliva and nasopharyngeal swab samples
Could an antidepressant slow COVID-19 progression?
RI-MUHC researchers launch a clinical trial of fluvoxamine, a drug that has already proven efficient in reducing lung injury in animal studies and...
Clinical Innovation Platform at the RI-MUHC announces first member company
Health tech accelerator welcomes AltPAP Innovation to its new state-of-the-art facility
Could a different testing strategy reduce healthcare workers’ isolation after unprotected exposure to a confirmed case of COVID-19?
RI-MUHC study suggests appropriate...
Haply wins the CODE LiFE Ventilator Challenge
What’s next? “Gather the resources to bring the Haply device to millions around the world,” says Reza Farivar